Evidence map›Paper›PMID 30514682›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2018

[PSB0739 inhibits formation of semen-derived amyloid fibril].

Yan Lan, Zichao Yang, Han Liu, Hongyan Cheng, Shuwen Liu, Suiyi Tan

Abstract read
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yan LanSchool of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Zichao YangSchool of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Han LiuSchool of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Hongyan ChengSchool of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Shuwen LiuSchool of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Suiyi TanSchool of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore the inhibitory effect of PSB0739 on the formation of semen-derived amyloid fibrils.

methodsPAP248-286 (440 μmol/L) was incubated with PSB0739 at different concentrations, and at different time points of incubation, aliquots were taken from each sample for Congo red staining to detect the formation of amyloid fibers. The morphology of amyloid fibrils incubated in the presence or absence of PSB0739 was visualized using transmission electron microscope. The effect of PSB0739 on amyloid fibril formation was determined using virus infection assays at different time points, and the surface charges of amyloid fibril incubated with PSB0739 were calculated using a Zeta potentiometer. The cytotoxicity of PSB0739 in Hela cells was determined using MTT assay. The antiviral effect of PSB0738 against HIV- 1 was evaluated by infection assay.

resultsPSB0739 inhibited SEVI fibril formation in a dose-dependent manner

conclusionsPSB0739 can inhibit the formation of semen-derived amyloid fibrils

Indexed as

AmyloidAnti-HIV AgentsDose-Response Relationship, DrugHeLa CellsHIV-1HIV InfectionsHumansIn Vitro TechniquesMicroscopy, Electron, TransmissionPurinergic P2Y Receptor AntagonistsSemenAmyloidAnti-HIV AgentsPurinergic P2Y Receptor Antagonistsamyloid fiberHIV-1PSB0739semensexual transmission

Identifiers

PMID30514682
PMCPMC6744116

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.